Construction of a Prognostic Immune Signature for Squamous-Cell Lung Cancer to Predict Survival

Rui-Lian Chen,Jing-Xu Zhou,Yang Cao,Ling-Ling Sun,Shan Su,Xiao-Jie Deng,Jie-Tao Lin,Zhi-Wei Xiao,Zhuang-Zhong Chen,Si-Yu Wang,Li-Zhu Lin
DOI: https://doi.org/10.3389/fimmu.2020.01933
IF: 7.3
2020-09-15
Frontiers in Immunology
Abstract:<span><b>Background:</b> Limited treatment strategies are available for squamous-cell lung cancer (SQLC) patients. Few studies have addressed whether immune-related genes (IRGs) or the tumor immune microenvironment can predict the prognosis for SQLC patients. Our study aimed to construct a signature predict prognosis for SQLC patients based on IRGs.<b>Methods:</b> We constructed and validated a signature from SQLC patients in The Cancer Genome Atlas (TCGA) using bioinformatics analysis. The underlying mechanisms of the signature were also explored with immune cells and mutation profiles.<b>Results:</b> A total of 464 eligible SQLC patients from TCGA dataset were enrolled and were randomly divided into the training cohort (<i>n</i> = 232) and the testing cohort (<i>n</i> = 232). Eight differentially expressed IRGs were identified and applied to construct the immune signature in the training cohort. The signature showed a significant difference in overall survival (OS) between low-risk and high-risk cohorts (<i>P</i> &lt; 0.001), with an area under the curve of 0.76. The predictive capability was verified with the testing and total cohorts. Multivariate analysis revealed that the 8-IRG signature served as an independent prognostic factor for OS in SQLC patients. Naive B cells, resting memory CD4 T cells, follicular helper T cells, and M2 macrophages were found to significantly associate with OS. There was no statistical difference in terms of tumor mutational burden between the high-risk and low-risk cohorts.<b>Conclusion:</b> Our study constructed and validated an 8-IRG signature prognostic model that predicts clinical outcomes for SQLC patients. However, this signature model needs further validation with a larger number of patients.</span>
immunology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to construct a prognostic immune signature model based on immune - related genes (IRGs) to predict the survival of patients with lung squamous cell carcinoma (SQLC). Specifically, the researchers aim to identify biomarkers that can predict the prognosis of SQLC patients by analyzing immune - related genes and the tumor immune microenvironment (TIME). This research is of great significance for improving the clinical treatment effect of SQLC patients, especially in immunotherapy, because the existing treatment methods have limited efficacy for SQLC patients and lack effective prognostic prediction tools. The key points of the paper include: - **Research background**: Treatment options for SQLC patients are limited and the prognosis is poor. Although immune checkpoint inhibitors have shown significant clinical benefits in some cancer types, an effective prognostic prediction model for SQLC patients still needs to be developed. - **Methods**: The researchers used the data in The Cancer Genome Atlas (TCGA) database to construct and validate a prognostic model based on 8 differentially expressed immune - related genes through bioinformatics analysis. - **Results**: This model showed good prognostic prediction ability in the training cohort, the test cohort and the total cohort, and multivariate analysis showed that these 8 IRG features can be used as independent prognostic factors for overall survival (OS) of SQLC patients. - **Conclusion**: The study successfully constructed and validated a prognostic immune signature model based on 8 IRGs, which can effectively predict the clinical outcome of SQLC patients. However, this model still needs to be further validated in a larger patient population, especially in Asian patients. Through these studies, the authors hope to provide more accurate immunotherapy regimens for SQLC patients and provide valuable references for future research.